# US 7,744,897 B2 · Human immunodeficiency virus gp41 mimetibody polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,744,897 B2
- Document ID: US7744897B2
- Status: Granted
- Kind: B2
- Application number: 11/018,102
- Filed: 2004-12-21
- Published: 2005-06-23
- Granted: 2010-06-29
- Earliest claimed: 2003-12-23
- Inventors: Susan B. Dillon; Alfred Michael Del Vecchio; Chichi Huang; Karyn T. O'Neil; Robert T. Sarisky
- Web page: https://patentgrep.com/patent/US7744897B2

## CPC

- C07K 14/005: from viruses
- A61P 1/12: Antidiarrhoeals
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2319/00: Fusion polypeptide
- C07K 2319/035: containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

HIV gp41 mimetibody polypeptides and encoding polynucleotides are disclosed. Methods of utilizing the polypeptides to reduce or inhibit HIV fusion with a cell membrane and entry into target cells are also disclosed.

## Claims

### Claim 1

A polypeptide having an amino acid sequence shown in SEQ ID NO: 1.

### Claim 2 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide is post-translationally modified.

### Claim 3 (depends on 2)

The polypeptide of claim 2 modified by the addition of polyethylene glycol moieties.

### Claim 4 (depends on 1)

A cell line expressing the polypeptide of claim 1.

### Claim 5 (depends on 4)

The cell line of claim 4 wherein the cell line is HEK293, NS0, SP2/0, CHO or Lemna cells.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising an effective amount of at least one polypeptide as in claim 1 and a pharmaceutically acceptable carrier or diluent.